ISAL 2017 | Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
Kristoffer Hellstrand, MD, PhD from the University of Gothenburg, Gothenburg, Sweden gives an overview of remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in acute myeloid leukemia (AML) at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. Prof. Hellstrand explains that one of the problems with AML is that even though patients can go into remission, they will relapse later on. The methods to prevent or delay relapse are lacking as Prof. Hellstrand further explains. Histamine dihydrochloride (Ceplene) together with low-dose IL-2 therapy is used as combination immunotherapy in patients who have achieved complete remission (CR) aiming to prevent relapse; the benefits of this combination was shown in Phase III trial (NCT00003991).
